CA2224634A1 - Prothrombin derivatives - Google Patents

Prothrombin derivatives Download PDF

Info

Publication number
CA2224634A1
CA2224634A1 CA002224634A CA2224634A CA2224634A1 CA 2224634 A1 CA2224634 A1 CA 2224634A1 CA 002224634 A CA002224634 A CA 002224634A CA 2224634 A CA2224634 A CA 2224634A CA 2224634 A1 CA2224634 A1 CA 2224634A1
Authority
CA
Canada
Prior art keywords
thrombin
prothrombin
hirudin
amino acid
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002224634A
Other languages
English (en)
French (fr)
Inventor
Artur Mitterer
Falko-Gunter Falkner
Uwe Schlokat
Bernhard Fischer
Johann Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2224634A1 publication Critical patent/CA2224634A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002224634A 1995-06-13 1996-06-12 Prothrombin derivatives Abandoned CA2224634A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0100695A AT404357B (de) 1995-06-13 1995-06-13 Prothrombin-derivate
ATA1006/95 1995-06-13

Publications (1)

Publication Number Publication Date
CA2224634A1 true CA2224634A1 (en) 1996-12-27

Family

ID=3504770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002224634A Abandoned CA2224634A1 (en) 1995-06-13 1996-06-12 Prothrombin derivatives

Country Status (9)

Country Link
US (1) US6086871A (cs)
EP (1) EP0833897A2 (cs)
JP (1) JPH11507542A (cs)
AT (1) AT404357B (cs)
AU (1) AU700631B2 (cs)
CA (1) CA2224634A1 (cs)
CZ (1) CZ402097A3 (cs)
HU (1) HUP9900506A3 (cs)
WO (1) WO1996041868A2 (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452768C (en) * 2001-07-06 2011-06-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for preparing human thrombin by genetic engineering technique
AU2008202376B2 (en) * 2001-07-06 2011-02-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing human thrombin by gene modification technique
US20030099957A1 (en) * 2001-09-28 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
WO2006104398A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
JPWO2008059917A1 (ja) 2006-11-15 2010-03-04 チッソ株式会社 トロンビン変異体
PL3078743T3 (pl) 2007-09-28 2020-11-02 Portola Pharmaceuticals, Inc. Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania
EP2344174B1 (en) * 2008-10-27 2016-04-27 Trustees Of Tufts College Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds, and uses thereof
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
EP3604510A1 (en) 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
EP2471945A1 (de) * 2010-12-30 2012-07-04 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Bestimmung von Inhibitoren der Gerinnung
JP2014515740A (ja) 2011-03-30 2014-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝固薬の解毒剤
CN104470532A (zh) * 2012-04-17 2015-03-25 奥胡斯大学 SorCS1在治疗肥胖症及超重中的应用
GB2504499A (en) * 2012-07-31 2014-02-05 Baxter Healthcare Sa Selective measurement of active human protease coagulation factors
WO2015183085A1 (en) 2014-05-26 2015-12-03 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
CA2000887A1 (en) * 1988-11-01 1990-05-01 Cecilia S.L. Ku Thromboresistant materials and methods for making same
ATE119195T1 (de) * 1989-01-25 1995-03-15 Ciba Geigy Ag Monoklonale antikörper, spezifisch für hirudin.
WO1991011519A1 (en) * 1990-01-26 1991-08-08 Immuno Aktiengesellschaft Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
AT401270B (de) * 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna

Also Published As

Publication number Publication date
US6086871A (en) 2000-07-11
EP0833897A2 (de) 1998-04-08
JPH11507542A (ja) 1999-07-06
WO1996041868A2 (de) 1996-12-27
ATA100695A (de) 1998-03-15
HUP9900506A2 (hu) 1999-06-28
AU700631B2 (en) 1999-01-07
AU5887196A (en) 1997-01-09
WO1996041868A3 (de) 1997-04-10
AT404357B (de) 1998-11-25
HUP9900506A3 (en) 2001-10-29
CZ402097A3 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
AU700631B2 (en) Prothrombin derivatives
EP2390323B1 (en) Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US7122634B2 (en) Modified factor VIII
US5106833A (en) Coagulation inhibitors
Citarella et al. Structure/function analysis of human factor XII using recombinant deletion mutants: evidence for an additional region involved in the binding to negatively charged surfaces
JPH10117787A (ja) ファクターｖｉｉ活性を有する蛋白質の製造方法
JP2003508019A (ja) 修飾されたｖｉｉｉ因子
JPH05508150A (ja) 酸化抵抗性トロンボモジュリン類縁体
IL84928A (en) Preparations and methods for synthesis and encaplase testing
HUT74873A (en) Factor vii-derived peptides
Girard et al. Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2
US6624289B1 (en) Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
EP2123670A1 (en) Anticoagulant polypeptide
US7109170B2 (en) Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
CA2150909A1 (en) Clotting inhibitor made from protostomia saliva
Narayanan Inhibition of in vitro platelet aggregation and release and fibrinolysis
RU2122583C1 (ru) Способ получения белка, обладающего опосредованной фактором vii активностью в свертывании крови
US6841534B2 (en) Protein Z-dependent protease inhibitor
US7060484B1 (en) Polypeptides and coagulation therapy
Monroe et al. Activation of normal and abnormal human factor IX with trypsin
WO2006031226A1 (en) Region of factor ixa protease domain that interacts with factor viiia and methods therefor
Lawson Tissue factor dependent hemostasis
Kaplan et al. Molecular mechanisms in allergy and clinical immunology
Huang Mutational studies of factor X activation by tissue factor-factor VIIa
Côté Studies of structure-function relationships in two human coagulation proteins: factor XII and prothrombin

Legal Events

Date Code Title Description
FZDE Discontinued